// Biotech and Pharma Therapeutics
Sarepta CEO Doug Ingram To Step Down as Muscular Dystrophy Mission Hits Home
February 25, 2026 / Sarepta Therapeutics Leadership Change / Duchenne Muscular Dystrophy Gene Therapy / Elevidys FDA Approval / Myotonic Dystrophy DM1 / Rare Neuromuscular Disease Innovation
Sarepta CEO Doug Ingram will step down amid personal family diagnoses of myotonic dystrophy (DM1). Under his leadership, Sarepta advanced multiple Duchenne muscular dystrophy therapies, including gene therapy Elevidys, despite complex clinical and regulatory challenges.
Cabenuva ‘an important alternative’ to daily pill for adelescents
February 25, 2026 / Cabenuva Long-Acting Injectable / Adolescent HIV Treatment / Cabotegravir Rilpivirine LA / HIV Viral Suppression 96 Weeks / Long-Acting Antiretroviral Therapy
In the Phase I/II IMPAACT 2017 trial, 94.4% of adolescents with HIV maintained viral suppression at 96 weeks after switching to long-acting injectable cabotegravir plus rilpivirine, with strong patient preference over daily oral therapy, supporting adherence-enhancing treatment alternatives.
Novartis Names Texas City as Location of Its 5th US Radiopharmaceutical Facility
February 25, 2026 / Radiopharmaceutical Manufacturing Expansion / Radioligand Therapy Production / Pluvicto and Lutathera Supply / Precision Oncology Infrastructure / Prostate Cancer Targeted Therapy
Novartis will build a Texas radiopharmaceutical facility to expand U.S. manufacturing of radioligand therapies, including Lutathera and Pluvicto, addressing time-sensitive isotope decay and strengthening regional access to targeted treatments for neuroendocrine tumors and prostate cancer.
Alkermes’ Richard Pops to step down after three-decade run as CEO
February 25, 2026 / Alkermes Leadership Transition / Orexin Sleep Therapy Development / Schizophrenia Treatment Lybalvi / Narcolepsy Late-Stage Trial / CNS Drug Pipeline Expansion
Alkermes CEO Richard Pops will step down after three decades, transitioning leadership as the company focuses on schizophrenia, addiction, and emerging orexin-based sleep therapies, following financial stabilization and expansion into late-stage narcolepsy and CNS drug development.
Charles River Laboratories to Sell Select European Discovery Services and CDMO Assets
February 25, 2026 / Charles River Divestiture Strategy / CDMO Gene Therapy Manufacturing / Drug Discovery Services Europe / Cell Therapy Development Services / CRO Portfolio Optimization
Charles River Laboratories will divest select European discovery services and CDMO/cell therapy assets, streamlining operations while retaining core drug discovery capabilities, including oncology and neuroscience research, and gene-modified cell therapy manufacturing services.
// 4th Industrial Revolution
Zimmer Biomet says its SynTuition algorithm enhances diagnostic certainty
February 25, 2026 / Periprosthetic Joint Infection Diagnosis / SynTuition Machine Learning Algorithm / AI in Orthopedic Infection / Synovial Biomarker Testing / Revision Surgery Cost Reduction
Zimmer Biomet’s SynTuition machine-learning algorithm improved diagnostic accuracy and reduced uncertainty in periprosthetic joint infection, achieving 96% concordance with expert diagnosis and lowering projected unnecessary revision surgeries by generating patient-specific infection probability scores.
The benefits of incorporating PGHD into clinical workflows
February 25, 2026 / Patient-Generated Health Data / PGHD Clinical Integration / Remote Patient Monitoring / Digital Health Interoperability / Chronic Disease Management Analytics
Integrating patient-generated health data (PGHD) into clinical workflows enhances real-time monitoring, supports earlier intervention, improves chronic disease management, and strengthens shared decision-making, provided data governance, interoperability, and clinician workflow alignment are effectively addressed.
Zyxel announces RCE patches for numerous network devices
February 25, 2026 / Healthcare Cybersecurity Vulnerability / HIPAA-Compliant Network Devices / Remote Code Execution Patch / Medical Network Security / Protected Health Information Safeguards
Zyxel issued critical patches for HIPAA-compliant routers and gateways addressing unauthenticated remote code execution vulnerabilities, underscoring cybersecurity risks to healthcare networks and the importance of securing connected clinical and patient data systems.
After gene therapy exit, Pfizer locks in global license for Beam gene editing candidate
February 25, 2026 / Pfizer Beam Gene Editing Deal / In Vivo Base Editing Therapy / Liver-Targeted Lipid Nanoparticle / Genome Editing Regulatory Pathway / Rare Genetic Liver Disease Treatment
Pfizer exercised its global license option for Beam’s liver-targeted in vivo base editing candidate, assuming development and commercialization responsibilities, reflecting renewed investment in genome editing technologies amid evolving FDA guidance for rare and genetic liver diseases.
Labcorp expands PathAI pact to roll out digital pathology platform in US
February 25, 2026 / Digital Pathology Platform Deployment / PathAI AISight Dx / AI in Anatomic Pathology / Labcorp Diagnostic Innovation / Slide Review Workflow Automation
Labcorp expanded its partnership with PathAI to deploy the AISight Dx digital pathology platform across U.S. anatomic pathology labs, enabling AI-supported slide review, case management, and collaborative diagnostics to enhance workflow efficiency and diagnostic precision.
// Business & Markets
Quantum Surgical buys J&J’s NeuWave
Feburary 25, 2026 / Robot-Assisted Tumor Ablation / Quantum Surgical Acquisition / NeuWave Medical Technology / Minimally Invasive Cancer Treatment / Oncology Robotics Innovation
Quantum Surgical acquired Johnson & Johnson’s NeuWave Medical to expand robot-assisted tumor ablation technologies, aiming to enhance precision oncology interventions and broaden access to minimally invasive cancer treatments that may reduce cancer-related morbidity and mortality
After 4-Week Strike, Kaiser Permanente Workers Score Tentative Win on Staffing & Pay
Feburary 25, 2026 / Kaiser Permanente Nurse Strike / Healthcare Staffing Ratios / Patient Safety and Staffing / Nurse Workforce Shortage / Hospital Labor Agreement
After a four-week strike, 31,000 Kaiser Permanente healthcare workers reached a tentative agreement addressing chronic understaffing, wage concerns, and patient safety, including elimination of “paper staffing” and creation of an internal nurse registry to improve bedside coverage.
GSK to acquire 35Pharma in $950M deal for cardiovascular drug
February 25, 2025 / Pulmonary Arterial Hypertension Therapy / Activin Signaling Inhibitor HS235 / GSK 35Pharma Acquisition / Cardiovascular Drug Development / Vascular Remodeling Treatment
GSK will acquire 35Pharma for up to $950 million to advance HS235, an activin signaling inhibitor entering pulmonary hypertension trials, targeting vascular remodeling with potential cardiovascular and metabolic benefits and reduced bleeding risk versus existing therapies.
Novo Nordisk Commits Up to $2B to Drug Delivery Startup Vivtex for R&D of Oral Metabolic Meds
February 25, 2026 / Oral GLP-1 Drug Delivery / Vivtex Intestinal Absorption Technology / Novo Nordisk Metabolic Pipeline / Peptide Bioavailability Enhancement / AI-Driven Drug Formulation
Novo Nordisk will invest up to $2.1 billion to license Vivtex’s AI-enabled oral drug delivery platform, aiming to enhance intestinal absorption of peptide-based metabolic therapies and improve dosing convenience for obesity and diabetes treatments.
Vir Biotechnology leaps on news of Astellas collaboration
Astellas and Vir Biotechnology formed a global collaboration to advance VIR-5500, a dual-masked CD3 T-cell engager targeting PSMA in prostate cancer, with shared development costs and transition of clinical leadership to Astellas following Phase I studies.
// Legal & Regulatory
15 states sue HHS over changes to childhood vaccine schedule
February 25, 2026 / Childhood Immunization Schedule Changes / ACIP Vaccine Policy Dispute / Vaccine Uptake and Public Health / Vaccine-Preventable Disease Risk / HHS Immunization Lawsuit
Fifteen states sued HHS over revisions to the U.S. childhood immunization schedule and restructuring of ACIP, arguing the changes undermine evidence-based vaccine policy, risk reduced uptake, and increase vaccine-preventable disease and healthcare system burden.
Novartis settles 18-month-old lawsuit from estate of Baltimore woman whose cells were extracted 75 years ago
February 24, 2026 / Henrietta Lacks HeLa Cells / Informed Consent in Medical Research / Biopharmaceutical Ethics Litigation / Human Tissue Commercialization / Bioethics and Health Equity
Novartis settled a lawsuit from the Henrietta Lacks estate over commercial use of HeLa cells obtained without consent in 1951, highlighting ongoing ethical, legal, and bioequity issues surrounding human tissue research and biopharmaceutical innovation.
AbbVie’s $100B US deal and FDA reforms highlight growing focus on domestic manufacturing
February 25, 2026 / US Pharmaceutical Manufacturing Expansion / AbbVie $100B Agreement / FDA Manufacturing Reforms / Drug Pricing Policy Shift / Biologics Supply Chain Resilience
AbbVie’s $100 billion agreement linking domestic manufacturing expansion to tariff exemptions and pricing flexibility, alongside FDA manufacturing reforms, signals a strategic shift toward strengthening U.S. drug supply resilience, advanced biologics production, and long-term pharmaceutical innovation capacity.
15 states sue RFK Jr. and CDC, challenging new childhood vaccine recommendations
February 25, 2025 / Childhood Vaccine Schedule Lawsuit / ACIP Advisory Committee Controversy / CDC Immunization Policy Changes / Vaccine-Preventable Disease Risk / Public Health Legal Challenge
Fifteen states sued RFK Jr., HHS, and the CDC over revised childhood vaccine recommendations that removed multiple universal immunizations, alleging unlawful restructuring of ACIP and insufficient scientific justification, with concerns about reduced vaccine uptake and increased preventable disease risk.
FDA grants full approval to Pfizer’s Braftovi combo
February 17, 2026 / BRAF V600E Metastatic Colorectal Cancer / Encorafenib Cetuximab Combination / BREAKWATER Phase III Trial / Targeted Therapy mCRC / FDA Full Approval Oncology
The FDA granted full approval to encorafenib (Braftovi) plus cetuximab and chemotherapy for BRAF V600E–mutated metastatic colorectal cancer, based on Phase III BREAKWATER data demonstrating significant improvements in progression-free and overall survival.
// Research & Development
Palvella Therapeutics Announces Positive Topline Results from Phase 3 SELVA Clinical Study of QTORIN™ 3.9% Rapamycin Anhydrous Gel in Microcystic Lymphatic Malformations
February 24, 2026 / Microcystic Lymphatic Malformations Treatment / QTORIN Rapamycin Gel / mTOR Pathway Inhibition / Phase 3 SELVA Trial / Rare Vascular Malformation Therapy
Phase 3 SELVA results show topical QTORIN™ 3.9% rapamycin significantly improved microcystic lymphatic malformations, meeting primary and secondary endpoints with favorable tolerability and minimal systemic exposure, supporting planned NDA submission as a potential first FDA-approved therapy.
New drug target discovered for devastating “brain on fire” disease
February 25, 2026 / Anti-NMDA Receptor Encephalitis / Autoimmune Brain Inflammation / NMDA Receptor Antibodies / Neuropsychiatric Autoimmune Disorder / Targeted Immunotherapy Development
Researchers identified a novel therapeutic target in anti-NMDA receptor encephalitis (“Brain on Fire”), an autoimmune disorder in which antibodies attack NMDA receptors, causing neuropsychiatric symptoms, seizures, and potential mortality, opening avenues for more targeted immunotherapies.
New brain stimulation approach could treat depression in just 5 days
February 25, 2025 / Accelerated TMS Protocol / Treatment-Resistant Depression Therapy / Transcranial Magnetic Stimulation / Major Depressive Disorder Treatment / Rapid Neuromodulation Approach
An accelerated transcranial magnetic stimulation (TMS) protocol delivering five daily sessions over five days produced antidepressant effects comparable to standard six-week treatment, suggesting a faster, potentially more accessible neuromodulation option for major depressive disorder.
Microplastics found in 90% of prostate cancer tumors, study reveals
February 25, 2025 / Microplastics and Prostate Cancer / Environmental Carcinogen Exposure / Tumor Tissue Contamination / Plastic Particles in Cancer / Oncologic Environmental Risk Factors
A study detected microplastics in 90% of prostate cancer tumors, with concentrations approximately 2.5-fold higher than adjacent healthy tissue, suggesting possible environmental contributions to tumorigenesis and warranting further investigation into carcinogenic mechanisms.
114 Injuries Tied to Trividia Health Glucose System Correction
February 24, 2025 / TRUE METRIX Glucose Meter Recall / Hyperglycemia E-5 Error Code / Blood Glucose Monitoring Safety / Medical Device Correction Alert / Diabetes Device Adverse Events
Trividia Health issued a correction for TRUE METRIX glucose systems after 114 serious injuries and one death linked to E-5 error code misinterpretation, emphasizing immediate medical attention for symptomatic hyperglycemia to prevent delayed treatment and severe complications.
// Politics
Trump administration pauses some Medicaid funding to Minnesota, citing fraud concerns
February 25, 2026 / Medicaid Funding Suspension / Healthcare Access for Low-Income Patients / CMS Fraud Oversight / Public Health Policy Impact / Medicaid Program Integrity
The Trump administration temporarily paused $259.5 million in Medicaid funding to Minnesota citing fraud concerns, raising potential risks to healthcare access for low-income populations reliant on Medicaid for essential medical services.
How Healthcare Leaders Responded to Trump’s State of the Union
February 25, 2026 / Prescription Drug Price Transparency / Most-Favored-Nation Drug Policy / Affordable Care Act Debate / Healthcare Cost Reform / TrumpRx Prescription Discounts
Healthcare leaders responded variably to President Trump’s State of the Union remarks, supporting prescription drug price transparency and Most-Favored-Nation policies while raising concerns about criticism of the Affordable Care Act and potential impacts on health coverage access.
Trump’s State of the Union trumpets healthcare greatest hits, but no new policies
February 25, 2026 / Affordable Care Act Criticism / Health Insurance Affordability Debate / Prescription Drug Cost Reform / Healthcare Subsidy Policy Proposal / U.S. Healthcare Cost Crisis
President Trump’s State of the Union reiterated criticism of the Affordable Care Act and promoted drug pricing reforms, including direct subsidy proposals, but introduced no new healthcare policies, despite ongoing concerns about insurance affordability and rising medical costs.
Why The Supreme Court’s Skinny-Label Ruling Matters
February 25, 2026 / Skinny Label Generic Litigation / Induced Infringement Supreme Court / Pharmaceutical Patent Law / Carved-Out Indications Dispute / Hikma Amarin Case
The Supreme Court’s review of Hikma v. Amarin addresses induced infringement in skinny-label generics, potentially clarifying how carved-out patented indications are protected and shaping future pharmaceutical patent enforcement and generic market entry strategies.
Surgeon general nominee and senator face off over vaccines and ‘shared decision-making’
February 25, 2026 / Surgeon General Confirmation Hearing / Vaccine Shared Decision-Making Debate / Chronic Disease Prevention Policy / MAHA Movement Public Health / U.S. Vaccine Policy Discussion
During her confirmation hearing, Surgeon General nominee Casey Means emphasized chronic disease prevention and “shared decision-making” on vaccines, reflecting broader debate within the MAHA movement over balancing public health guidance with individualized risk assessment and preventive health priorities.